Among these, IL‐6, whose role is supported by a recent report of refractory SS being managed with tocilizumab [44], has been shown to be overexpressed in SS serum, especially during the active stages of the disease [26, 28, 31]. This evidence concerns the gene IL6 and synovial sarcoma.